Status:

COMPLETED

A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population

Lead Sponsor:

Braintree Laboratories

Conditions:

Colonoscopy

Eligibility:

All Genders

6-16 years

Phase:

PHASE4

Brief Summary

This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routin...

Eligibility Criteria

Inclusion

  • Male or female patients who are undergoing colonoscopy for a routinely accepted indication, including:
  • Evaluation of BE results
  • Endosonography
  • Blood in stool
  • Anemia of unknown etiology
  • Abdominal Pain
  • Polypectomy
  • Unknown diarrhea or constipation etiology
  • Inflammatory bowel disease
  • Between 6 and 16 years of age at screening.
  • Otherwise in good health, as determined by physical exam and medical history.
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse).
  • Negative urine pregnancy test at screening, if applicable
  • In the investigator's judgment, parent/guardian is mentally competent to provide informed consent to participate in the study.

Exclusion

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon
  • Subjects impacted at screening
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal and decompression
  • Subjects with known difficulties for swallowing tablets
  • Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics.
  • Subjects who are taking drugs that may affect electrolyte levels with the exception of routine diuretics.
  • Subjects with known clinically significant electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
  • Any condition in parent/guardian associated with poor subject compliance (e.g., substance abuse); inability of parent/guardian to return for scheduled visits with their child.

Key Trial Info

Start Date :

January 1 2007

Trial Type :

INTERVENTIONAL

End Date :

May 1 2007

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00425594

Start Date

January 1 2007

End Date

May 1 2007

Last Update

December 27 2007

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Birmingham, Alabama, United States, 35233

2

Mobile, Alabama, United States, 36604

3

Tuscaloosa, Alabama, United States, 35406

4

Phoenix, Arizona, United States, 85016